Literature DB >> 20470935

Low-abundant adiponectin receptors in visceral adipose tissue of humans and rats are further reduced in diabetic animals.

Sabrina Bauer1, Johanna Weigert, Markus Neumeier, Josef Wanninger, Andreas Schäffler, Andreas Luchner, Andreas A Schnitzbauer, Charalampos Aslanidis, Christa Buechler.   

Abstract

BACKGROUND AND AIMS: Adipose tissue is an endocrine organ that releases various proteins that may also exert autocrine/paracrine effects. The antidiabetic adipokine adiponectin acts through two receptors, AdipoR1 and AdipoR2, but so far mainly mRNA expression has been measured in adipocytes and adipose tissues. Therefore, we aimed to analyze AdipoR1 and AdipoR2 proteins in adipocytes and paired samples of subcutaneous and visceral adipocytes/adipose tissue.
METHODS: AdipoR1 and AdipoR2 mRNA and protein expression were determined in adipocytes and paired samples of subcutaneous and visceral adipose tissue of humans and rats.
RESULTS: AdipoR1 and AdipoR2 proteins were similarly abundant in preadipocytes and mature adipocytes despite an induction of mRNA expression during differentiation. Differentiation of 3T3-L1 cells in the presence of palmitic acid did not alter adiponectin receptor proteins but metformin and fenofibrate upregulated AdipoR2 within 24 h of incubation. AdipoR2 protein was significantly lower in human visceral compared to subcutaneous fat, and both receptors were reduced in visceral adipocytes. In rat tissues both receptors were reduced in visceral fat. In diabetic animals AdipoR2 protein, but not mRNA, was lower in both fat depots compared to similarly obese rats with normal glucose disposal. AdipoR1 was only reduced in subcutaneous adipose tissue of diabetic animals where mRNA expression was induced.
CONCLUSIONS: These data indicate that mRNA expression is not suitable to predict adiponectin receptor protein. Low adiponectin receptors in visceral adipocytes and adipose tissue and further suppression in adipose tissue of insulin-resistant animals indicate disturbed adiponectin bioactivity. Copyright 2010 IMSS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20470935     DOI: 10.1016/j.arcmed.2010.02.010

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  11 in total

1.  Adiponectin receptor 1 enhances fatty acid metabolism and cell survival in palmitate-treated HepG2 cells through the PI3 K/AKT pathway.

Authors:  I-Pin Chou; Yuan Yu Lin; Shih-Torng Ding; Ching-Yi Chen
Journal:  Eur J Nutr       Date:  2013-10-16       Impact factor: 5.614

Review 2.  Adiponectin, a key adipokine in obesity related liver diseases.

Authors:  Christa Buechler; Josef Wanninger; Markus Neumeier
Journal:  World J Gastroenterol       Date:  2011-06-21       Impact factor: 5.742

Review 3.  From diabetes to renal aging: the therapeutic potential of adiponectin.

Authors:  Mehdi Karamian; Maryam Moossavi; Mina Hemmati
Journal:  J Physiol Biochem       Date:  2021-02-08       Impact factor: 4.158

4.  Increased estrogen receptor β in adipose tissue is associated with increased intracellular and reduced circulating adiponectin protein levels in aged female rats.

Authors:  Nanette J Tomicek; Timothy S Lancaster; Donna H Korzick
Journal:  Gend Med       Date:  2011-07-22

5.  Porcine adiponectin receptor 1 transgene resists high-fat/sucrose diet-induced weight gain, hepatosteatosis and insulin resistance in mice.

Authors:  Bing-Hsien Liu; Yuan-Yu Lin; Ya-Chin Wang; Chao-Wei Huang; Chih-Chien Chen; Shinn-Chih Wu; Harry J Mersmann; Winston T K Cheng; Shih-Torng Ding
Journal:  Exp Anim       Date:  2013

6.  Pepsin Egg White Hydrolysate Ameliorates Obesity-Related Oxidative Stress, Inflammation and Steatosis in Zucker Fatty Rats.

Authors:  M Garcés-Rimón; C González; J A Uranga; V López-Miranda; R López-Fandiño; M Miguel
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

Review 7.  Gender Differences in Adipocyte Metabolism and Liver Cancer Progression.

Authors:  Otto K-W Cheung; Alfred S-L Cheng
Journal:  Front Genet       Date:  2016-09-20       Impact factor: 4.599

Review 8.  A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease.

Authors:  Zhonge Chen; Rong Yu; Ying Xiong; Fangteng Du; Shuishan Zhu
Journal:  Lipids Health Dis       Date:  2017-10-16       Impact factor: 3.876

Review 9.  Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction.

Authors:  Arunkumar E Achari; Sushil K Jain
Journal:  Int J Mol Sci       Date:  2017-06-21       Impact factor: 5.923

Review 10.  Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue.

Authors:  Sofia Dias; Sílvia Paredes; Laura Ribeiro
Journal:  Int J Endocrinol       Date:  2018-01-17       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.